When parents have concerns about autism spectrum disorder, one of the hardest parts is often the waiting. Traditional autism evaluations are largely based on behavior, communication, and developmental milestones, which means clear answers may not come until well after the earliest months and years of life. NeuroQure’s ASD Insight™ test offers a different path by looking for a biological marker associated with autism risk, giving families the opportunity to learn more far earlier than standard behavioral assessment alone.
ASD Insight™ is designed to identify autism risk from a simple skin sample, including in children as young as newborns. Rather than waiting for social, communication, or behavioral patterns to become obvious over time, this test examines how certain cellular signaling pathways are functioning. NeuroQure’s findings centers on intracellular calcium signaling, specifically disruption involving the IP₃ receptor pathway, a measurable biomarker, present from birth in many forms of autism.
This matters because timing matters. Neurodevelopment happens rapidly in the earliest years of life. During this window, the brain is especially adaptable, and support introduced sooner may have a greater impact. Conventional behavioral assessments generally cannot be used reliably before 18 to 24 months, while the median age of diagnosis is around 5 years. Their goal with ASD Insight™ is to shorten that gap, giving families useful information while the brain is still in one of its most responsive stages of development.
For many families, earlier insight can mean earlier action. That does not mean rushing to conclusions. It means having another piece of information that can help guide closer observation, developmental support, and thoughtful planning. Screening at birth or early in life may help families access therapies, services, and resources sooner with research showing that intervention started before age 2 can improve long-term developmental outcomes compared with waiting until the more typical age of diagnosis.
One of the most exciting aspects of ASD Insight™ is that it brings objective biology into a space that has traditionally depended almost entirely on observation. Parents often know something feels “off” before anyone can put it into words, yet they may be told to wait and see. A biology-based test does not replace a full developmental evaluation, but it can add meaningful information much earlier in the process. ASD Insight™ is an autism risk test, not a stand-alone autism diagnosis, and it does not replace tools such as ADOS or other clinical assessments.
The testing process itself is relatively straightforward. The tissue sample is collected through a skin punch biopsy, or in some cases from discarded foreskin, and then sent to the NeuroQure, a CLIA-certified laboratory for analysis. The sample is processed using a patented calcium-signaling method, and results are typically returned within weeks through a secure online portal.
The science behind ASD Insight™ is rooted in 8 years of research at the University of California, Irvine’s Center for Autism Research and Translation. ASD Insight™ represents the first clinical-grade, biology-based test of its kind for autism risk detection, created to move the field beyond observation alone and toward measurable cellular markers. That is a meaningful shift, especially for parents who want clearer answers and a more proactive way to support their child’s development.
At East Valley Naturopathic Doctors, we believe families deserve timely information, compassionate guidance, and a root-cause mindset whenever possible. Unlike conventional models that often rely on waiting for symptoms to fully declare themselves, newer tools like ASD Insight™ may help open the door sooner. Earlier knowledge gives parents more time to ask questions, build the right care team, explore therapies, support communication and sensory needs, and make decisions from a place of clarity rather than uncertainty. Used wisely, this kind of testing can help families feel less stuck and more supported.
Contact East Valley Naturopathic Doctors today to schedule a consultation to discuss the option of ASD Insight™ for evaluation of your child.
What is the NeuroQure ASD Insight™ test?
The NeuroQure ASD Insight™ test is an early autism risk screening test. It looks for a specific cellular pattern linked with autism spectrum disorder (ASD). The goal is to identify risk earlier, so families and providers can watch development more closely and take action sooner when needed.
Is this a test that diagnoses autism?
No. ASD Insight™ does not diagnose autism. It is a risk test, which means it can show whether a child has a biological pattern associated with increased autism risk. It does not replace a full developmental evaluation or diagnostic tools such as ADOS. A positive result should be used as a reason for closer follow-up and monitoring.
How is ASD Insight™ different from traditional autism screening?
Traditional autism screening usually depends on watching a child’s behavior, communication, and development over time. ASD Insight™ is different because it looks at a biological signal in the body. This can offer insight earlier, even before some behavioral signs are easy to recognize.
How does the test work?
ASD Insight™ measures calcium signaling in cells. This signaling helps support many important body functions, including communication between nerve cells, energy production, immune function, and gut function. Research behind the test found that this signaling pattern is often lower or less stable in people with autism. The test looks for that pattern.
Is this a blood or genetic test?
No. ASD Insight™ is not a blood or genetic test. Genetic testing looks at DNA. ASD Insight™ looks at calcium signaling inside cells. That makes it a different kind of test than chromosome testing, microarray testing, or whole exome sequencing.
Who can take the ASD Insight™ test?
The test may be used for patients of nearly any age, except during pregnancy. It may be especially helpful in babies, toddlers, and preschool-age children, when early behavioral testing may be harder to complete or may not yet give clear answers.
What sample is needed for the test?
The test uses a small 3mm skin biopsy collected by a qualified healthcare professional. This is a very small sample of skin. A local anesthetic may be used to reduce discomfort during the procedure.
Where is the biopsy usually taken from?
The 3mm biopsy can be taken from different areas of the body. The upper thigh is one common location because the skin there is often a good thickness for sampling. Stitches are not needed for a 3 mm biopsy. Basic aftercare may include antibiotic cream and a bandage.
How accurate is the ASD Insight™ test?
The test detects an elevated autism risk signal in more than 80% of people with ASD and is negative in more than 78% of the general population. As with any medical test, no screening tool is perfect, so results should always be interpreted along with a child’s history, development, and clinical evaluation. The test does not identify a specific type of autism, and it does not predict symptom severity or behavioral features. It is designed to detect risk, not define how autism may look in a specific child.
What happens if the test result is positive?
A positive result means the autism risk signaling pattern was detected. It does not mean a child has already been formally diagnosed with autism. It does mean follow-up evaluation is recommended. Early developmental support, monitoring, and formal assessment can help a child access therapies and services as early as possible.
What if the test result is negative?
A negative result means the autism risk signal was not detected. That may lower the likelihood of a future autism diagnosis, but it does not completely rule it out. Children should still continue routine developmental screening and monitoring.
Is ASD Insight™ FDA approved?
According to the provided FAQ, ASD Insight™ has not been cleared or approved by the U.S. Food and Drug Administration. It was developed by NeuroQure as a clinical laboratory test and is used for clinical purposes.
Does insurance cover the test?
At this time, the provided FAQ states that the test is not covered by insurance and costs $949 out of pocket.
Why does early detection matter?
Early detection can lead to earlier support. When families and providers identify concerns sooner, children can be monitored more closely and referred for helpful therapies, educational resources, and developmental services earlier. That early support can make a meaningful difference.
